CagriSema Weight Loss: Early Responders Lose 25% in New REDEFINE 1 Analysis
Novo Nordisk ObesityWeek data show CagriSema users who lost 5% by week 8 reached 25.4% weight loss at 68 weeks, ahead of an FDA decision due in Q4 2026.
Tag: ObesityWeek 2026
Read More
Lilly ObesityWeek 2026 Data: EloraTZP Hits 23% Weight Loss, Retatrutide Tackles Sleep Apnea
Lilly’s ObesityWeek 2026 slate: EloraTZP up to 23.3% weight loss in type 2 diabetes, retatrutide cuts sleep apnea events by up to 60.6%, Zepbound data in teens.